Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

‘Mono’ means one and 'clone' means identical copy. Monoclonal antibodies are, therefore, identical copies of one type of antibody. Antibodies bind to specific antigens on pathogens. This means ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...